A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 106
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : DAPSA
Long Form : Disease Activity Index for Psoriatic Arthritis
No. Year Title Co-occurring Abbreviation
2022 Comparative performance of composite measures from two phase III clinical trials of ixekizumab in psoriatic arthritis. LDA, mCPDAI, MDA, PROs, VLDA
2022 Correlation of patient-reported routine assessment of patient index data with clinical measures of disease activity in psoriatic arthritis. MDA, PsA, RAPID3, ROC, VLDA
2022 Dactylitis Is Associated With More Severe Axial Joint Damage and Higher Disease Activity in Axial Psoriatic Arthritis. axPsA, OR
2022 Depression in psoriatic arthritis: Related to socio-demographics, comorbid loads or disease activity? HADS, HAQ-DI, PsA, taub
2022 Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis. LDA, MDA, PASDAS, PsA, VLDA
2022 Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial. BSA, EI, LDA, LDI, LEI, MDA, mNAPSI, PASDAS, PsA, SPARCC
2022 Impact of psoriasis remains important in psoriatic arthritis patients with low musculoskeletal disease activity. HRQoL, LDA, PASI
2022 Micronutrients deficiencies in patients with spondylarthritis: the potential immunometabolic crosstalk in disease phenotype. ASDAS-CRP, BMI, FA, Fe, HAQ-S, Hb, LDA, MNDs, SpA
2022 Minimal disease activity and remission in patients with psoriatic arthritis with elevated body mass index: an observational cohort study in the Swiss Clinical Quality Management cohort. BMI, cDAPSA, MDA, OR, PsA, SCQM
10  2022 Precision medicine based on the phenotypic differences in peripheral T helper cells in patients with psoriatic arthritis: One year follow-up outcomes. bDMARDs, LDA, MDA
11  2022 Predictive Value of Monocyte Chemoattractant Protein-1 in the Development of Diastolic Dysfunction in Patients with Psoriatic Arthritis. DD, MCP-1, PsA
12  2022 Real-World Effectiveness and Treatment Retention of Secukinumab in Patients with Psoriatic Arthritis and Axial Spondyloarthritis: A Descriptive Observational Analysis of the Spanish BIOBADASER Registry. AS, ASDAS, BASDAI, bDMARDs, DAS28-CRP, IL-17A, PsA, SJC, TJC
13  2022 Relationship between disease impact scores and C-reactive protein/albumin ratio in patients with psoriatic arthritis. AUC, CI, CRP, ESR, NLR, PLR, PsA, PsAID-12
14  2022 Responses to Ixekizumab in Male and Female Patients with Psoriatic Arthritis: Results from Two Randomized, Phase 3 Clinical Trials. LDA, MDA/VLDA, PsA, RCTs
15  2022 Serum Calprotectin as a Promising Inflammatory Biomarker in Psoriatic Arthritis: a 1-Year Longitudinal Study. AUC, CLP, ELISA, LDA, MDA, PASI, PGA, PsA, PsO, ROC, SJC, TJC, VAS
16  2022 Serum interleukin-23 levels: relation to depression, anxiety, and disease activity in psoriatic arthritis patients. HADS, MASEI, PASI, PsA
17  2022 Systemic Immune Inflammation Index as a Reliable Disease Activity Marker in Psoriatic Arthritis. MLR, NLR, PLR, PsA, ROC, SII
18  2022 The value of SPARCC sacroiliac MRI scoring in axial psoriatic arthritis and its association with other disease parameters. ASDAS, axPsA, BASDAI, CRP, MDA, MRI, SIJ, SIS, SPARCC
19  2022 Vaccination for SARS-CoV-2 in Patients With Psoriatic Arthritis: Can Therapy Affect the Immunological Response? BAU, HCW, PsA
20  2022 [Association of skin lesion severity with clinical features of psoriatic arthritis]. ASDAS, BSA, CREPAR, CRP, DAS28, ESR, HAQ, PASI, PsA
21  2021 Comparison of Composite Measure Remission Targets in Psoriatic Arthritis. cDAPSA, CPDAI, MDA, PsA, VAS, VLDA
22  2021 Depression and Endothelial Dysfunction in Psoriatic Arthritis: Is There Any Possible Relationship? aFRS, CVEs, FMD, HDS, PsA
23  2021 Effect of interleukin-17A inhibitor in Japanese patients with psoriatic arthritis compared with tumor necrosis factor-alpha inhibitor. CRP, IL-17Ai, mHAQ, PsA, SJC, TJC, TNFi, VAS
24  2021 Evaluation and Validation of a Patient-completed Psoriatic Arthritis Flare Questionnaire. CPDAI, FLARE, GRAPPA, ICC, PASDAS, PsA
25  2021 Fatigue in psoriatic arthritis: Is it related to disease activity? FACIT-F, PASI, PsA
26  2021 Impact of obesity on quality of life, psychological status, and disease activity in psoriatic arthritis: a multi‑center study. BASDAI, BMI, DAS28-CRP, FACIT, HADS, HAQ, HAQ-S, PASI, PsA, PsAQoL, VAS-F, VASP
27  2021 Implementation of the Treat-to-Target Concept in Evaluation of Psoriatic Arthritis Patients. MDA, PRO, PsA
28  2021 Performance of 3 Composite Measures for Disease Activity in Peripheral Spondyloarthritis. ASDAS, PASDAS, PsO, pSpA
29  2021 Prevalence of Depressive Symptoms in Patients With Psoriatic Arthritis: Have Numbers Changed During the COVID-19 Pandemic? PHQ-2
30  2021 Role of ultrasound for assessment of psoriatic arthritis patients with fibromyalgia. CPDAI, FMS, PASDAS, PsA, US
31  2021 Serum golimumab concentration and anti-drug antibodies are associated with treatment response and drug survival in patients with inflammatory joint diseases: data from the NOR-DMARD study. ADAbs, ASDAS, axSpA, EULAR, IJD, PsA, RA
32  2021 Treatment with Ixekizumab Following Secukinumab Failure in Patients with Psoriatic Arthritis: Real-Life Experience from a Resistant Population. PsA, SDAI, TJC, TNFi
33  2020 A proposal on how to assess the weight of the subjective components of the DAPSA in patients with psoriatic arthritis and comorbid fibromyalgia syndrome. DAPSA-P, FM, PsA, ROC
34  2020 Assessment of the Patient Acceptable Symptom State (PASS) in psoriatic arthritis: association with disease activity and quality of life indices. MDA, PASS, PsA, PsAID, VLDA
35  2020 Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis: protocol of a randomized, placebo-controlled, double-blind clinical trial (COMPLETE-PsA). ACR, DMARD, HAQ, LEF, MDA, MTX, PASDAS, PsA, PSAID, SF-12
36  2020 Comparison of remission and low disease activity states with DAPSA, MDA and VLDA in a clinical trial setting in psoriatic arthritis patients: 2-year results from the FUTURE 2 study. LDA, MDA, PROs, REM, VLDA
37  2020 Construct validity of the ASAS health index in psoriatic arthritis: a cross-sectional analysis. ASAS-HI, AUC, PsA, PsAID
38  2020 DAPSA, carotid plaque and cardiovascular events in psoriatic arthritis: a longitudinal study. CIMT, CP, CV, CVD, PsA
39  2020 Determinants of sleep impairment in psoriatic arthritis: An observational study with 396 patients from 14 countries. PR, PsA
40  2020 Disease Activity in Psoriatic Arthritis Index and Psoriatic Arthritis Impact of Disease Questionnaire: correlation and sensitivity to change in a real clinical setting. PsA, PsAID, SMR
41  2020 Efficacy and safety of a single switch from etanercept originator to etanercept biosimilar in a cohort of inflammatory arthritis. AE, AS, DAS28, HAQ, HAQ-S, PsA, RA
42  2020 HDL cholesterol efflux capacity is related to disease activity in psoriatic arthritis patients. CEC, HDL
43  2020 Impact of Comorbidities on Disease Activity, Patient Global Assessment, and Function in Psoriatic Arthritis: A Cross-Sectional Study. FM, HAQ-DI, MDA, PsA, PsAID, PtGA, SCC
44  2020 Impact of Disease Activity on Physical Activity in Patients With Psoriatic Arthritis. IPAQ, MVPA, PA, PsA
45  2020 Inhibition of radiographic progression across levels of composite index-defined disease activity in patients with active psoriatic arthritis treated with intravenous golimumab: results from a phase-3, double-blind, placebo-controlled trial. CDAI, MDA, PASDAS, PsA, VLDA
46  2020 Mismatch between the impact of disease perceived by patients and the state of clinical remission assessed by physicians in psoriatic arthritis. PASS, PsA, PsAID
47  2020 Patients with psoriatic arthritis have higher levels of FeNO than those with only psoriasis, which may reflect a higher prevalence of a subclinical respiratory involvement. FeNO, PsA
48  2020 Perceived influence of health status on sexual activity in patients with psoriatic arthritis. DLQI, MASES, mHAQ, PASI, PGA, PsA
49  2020 Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis. CDAI, MDA, PASDAS, PsA, SDAI, VLDA
50  2020 Power Doppler Ultrasound Assessment of A1 Pulley. A New Target of Inflammation in Psoriatic Arthritis? PD, PsA, RA, US
51  2020 Remission and low disease activity in psoriatic arthritis publications: a systematic literature review with meta-analysis. DAS28, LDA, PsA, REM, VLDA/MDA
52  2020 Serum calprotectin: a promising biomarker in rheumatoid arthritis and axial spondyloarthritis. ASDAS, axSpA, BASDAI, DAMP, DAS, HAQ, HC, PsA, RA, SCQM, SJC, US-PD
53  2020 Serum sCD40L levels are increased in patients with psoriatic arthritis and are associated with clinical response to apremilast. CI, LDA, LEI, OR, PASI, PDE4, PsA, SD
54  2020 The impact of fatigue on patients with psoriatic arthritis: amulti-center study of the TLAR-network. BASDAI, cDAPSA, DAS28, FACIT-F, FiRST, MDA, PsA, TLAR, VLDA
55  2020 Ultrasound assessment, unlike clinical assessment, reflects enthesitis in patients with psoriatic arthritis. CRP, HAQ, MMP-3, mTSS, PASE, PASI, PsA, US
56  2020 Ultrasound verified enthesophytes are associated with radiographic progression at entheses in psoriatic arthritis. PsA
57  2019 Association of synovial tissue polyfunctional T-cells with DAPSA in psoriatic arthritis. IFN-gamma, IL, PDE4, PsA, Th1
58  2019 Clinical and Ultrasound Assessment of Enthesis in Psoriatic Arthritis in a Romanian Cohort. BUSES, IBD, LEI, MSUS, PsA, ReA, SA, SpA, uSpA
59  2019 Comparison of disease activity measures in early psoriatic arthritis in usual care. CPDAI, DAS28, DEPAR, ES, GRACE, HRQoL, MDA, PASDAS, SRM
60  2019 Composite Measures of Disease Activity in Psoriatic Arthritis: Comparative Instrument Performance Based on the Efficacy of Guselkumab in an Interventional Phase II Trial. mCPDAI, PASDAS, PsA
61  2019 Determinants of Patient-Reported Psoriatic Arthritis Impact of Disease: An Analysis of the Association With Sex in 458 Patients From Fourteen Countries. MDA, NRS, OR, PsA, PsAID
62  2019 Disease activity and functional status associated with health-related quality of life and patient-acceptable symptom state in patients with psoriatic arthritis in Thailand: A cross-sectional study. cDAPSA, EQ-5D-5L, HAQ, HU, MDA, PASS, PsA
63  2019 Inhibition of radiographic progression in psoriatic arthritis by adalimumab independent of the control of clinical disease activity. ADA, MDA, PASDAS, PBO, TA
64  2019 Mediterranean diet and Psoriatic Arthritis activity: a multicenter cross-sectional study. BMI, CPDAI, MDS, PsA
65  2019 Progressive structural bone changes and their relationship with treatment in patients with psoriatic arthritis: a longitudinal HR-pQCT study. HR-pQCT, IL-17A, LDA, PsA, SDC, TNF-alpha
66  2019 PsA-Disk, a novel visual instrument to evaluate psoriatic arthritis in psoriatic patients: an Italian derma-rheuma multicentre study. DAS, ESR, HAQ, NAPSI, PGA, PsA, PsO, VAS
67  2019 Psoriatic and psoriatic arthritis patients with and without jet-lag: does it matter for disease severity scores? Insights and implications from a pilot, prospective study. DLQI, PASI, SAPASI, VAS
68  2019 Real-world Longterm Effectiveness of Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis Patients from the Rheumatic Diseases Portuguese Register. ASDAS, EULAR, MDA, PsA, TNFi
69  2019 Retrospective evaluation of patient profiling and effectiveness of apremilast in an Italian multicentric cohort of psoriatic arthritis patients. LDA, MDA, PsA, VLDA
70  2019 The contribution of joint and skin improvements to the health-related quality of life of patients with psoriatic arthritis: a post hoc analysis of two randomised controlled studies. HRQoL, PASI, PsA, VAS, WPAI
71  2019 The Impact of Intermittent Fasting (Ramadan Fasting) on Psoriatic Arthritis Disease Activity, Enthesitis, and Dactylitis: A Multicentre Study. BASDAI, CRP, DSS, LEI, PASI, PsA
72  2019 The relationship between patient acceptable symptom state and disease activity in patients with psoriatic arthritis. AUC, PASDAS, PASS
73  2019 Very Low Disease Activity, DAPSA Remission, and Impact of Disease in a Spanish Population with Psoriatic Arthritis. CASPAR, PsAID, VLDA
74  2018 Assessment of nail unit structures by ultrasound in patients with psoriatic arthritis and their correlations with disease activity indices: a case-control study. NAPSI, NBT, NMT, NPD, PASI, PsA
75  2018 Can disease activity in patients with psoriatic arthritis be adequately assessed by a modified Disease Activity index for PSoriatic Arthritis (DAPSA) based on 28 joints? CRP, PsA
76  2018 Comparing patient-perceived and physician-perceived remission and low disease activity in psoriatic arthritis: an analysis of 410 patients from 14 countries. LDA, MDA, PsA, VLDA
77  2018 DAPSA and ultrasound show different perspectives of psoriatic arthritis disease activity: results from a 12-month longitudinal observational study in patients starting treatment with biological disease-modifying antirheumatic drugs. CRP, EGA, ESR, GS, PD, PROMs, PsA, US
78  2018 Drug survival and effectiveness of ustekinumab in patients with psoriatic arthritis. Real-life data from the biologic Apulian registry (BIOPURE). BIOPURE, HRs, PsA, TNF-IR
79  2018 Residual symptoms and disease burden among patients with psoriatic arthritis: is a new disease activity index required? CRP, LDA, MDA, PsA, SJC, TJC
80  2018 Ten years of follow-up data in psoriatic arthritis: results based on standardized monitoring of patients in an ordinary outpatient clinic in southern Norway. CDAI, CRP, DMARD, ESR, PROs, PsA
81  2018 Ultrasonography of the nail unit reveals quantitative and qualitative alterations in patients with psoriasis and psoriatic arthritis. NAPSI, PASI
82  2017 Comparison of Composite Indices Tailored for Psoriatic Arthritis Treated with csDMARD and bDMARD: A Cross-sectional Analysis of a Longitudinal Cohort. bDMARD, cDAPSA, csDMARD, LDA, MDA, PASDAS, PsA
83  2017 DAPSA, DAS28 and MDA predict long-term treatment regime in psoriatic arthritis. The Swedish Early Psoriatic Arthritis Cohort. DAS28, DMARD, M/O, NSAID, SwePsA, TNFi, VAS
84  2017 Ideal target for psoriatic arthritis? Comparison of remission and low disease activity states in a real-life cohort. cDAPSA, LDA, MDA, PASI, PsA, SJC, TJC, VLDA
85  2017 Need for Improvement in Current Treatment of Psoriatic Arthritis: Study of an Outpatient Clinic Population. CASPAR, CPDAI, DAS28, DLQI, ESR, MDA, PASDAS, PASI, PsA, SDAI
86  2017 Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. ASDAS, MDA, PsA, SpA
87  2017 Value of the Routine Assessment of Patient Index Data 3 in Patients With Psoriatic Arthritis: Results From a Tight-Control Clinical Trial and an Observational Cohort. LOPAS II, MDA, PASDAS, PsA, RAPID3, TICOPA, VAS, VLDA
88  2016 Assessment of Response to Treatment, Remission, and Minimal Disease Activity in Axial Psoriatic Arthritis Treated with Tumor Necrosis Factor Inhibitors. anti-TNF, axPsA, BASDAI, CASPAR, CPDAI, MDA, PR
89  2016 Disease activity states of the DAPSA, a psoriatic arthritis specific instrument, are valid against functional status and structural progression. PsA, TNF
90  2016 Disease-modifying antirheumatic drugs improve cardiovascular autonomic neuropathy in psoriatic arthritis. CAN, DMARD, PsA
91  2016 Management of psoriatic arthritis: Early diagnosis, monitoring of disease severity and cutting edge therapies. CASPAR, CPDAI, DMARDs, EULAR, GRAPPA, JAK, PASE, PASQ, PEST, PsA, PsAJAI, TOPAS
92  2016 The Effect of the Presence of Fibromyalgia on Common Clinical Disease Activity Indices in Patients with Psoriatic Arthritis: A Cross-sectional Study. BASDAI, CPDAI, FM, HAQ, LEI, MDA, PsA
93  2016 Ultrasonographic evaluation in psoriatic arthritis is of major importance in evaluating disease activity. CPDAI, MDA, PASDAS, PD, PsA, US
94  2015 Disease activity and response assessment in psoriatic arthritis using the Disease Activity index for PSoriatic Arthritis (DAPSA). A brief review. PsA
95  2015 Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. CRP, MDA, PsA, REM
96  2015 Minimal Disease Activity and Remission in Psoriatic Arthritis Patients Treated with Anti-TNF-alpha Drugs. CASPAR, MDA, PsA
97  2015 Patient's Global Assessment as an Outcome Measure for Psoriatic Arthritis in Clinical Practice: A Surrogate for Measuring Low Disease Activity? CASPAR, LDA, MDA, PsA, PtGA, TNF-alpha
98  2014 Disease activity in psoriatic arthritis: comparison of the discriminative capacity and construct validity of six composite indices in a real world. CPDAI, CRP, ESR, HAQ, MDA, PASDAS, PASI, SDAI
99  2014 Remission criteria and activity indices in psoriatic arthritis. ACR/EULAR, CDAI, CI, CPDAI, DAS28, PASE, PsA, RA, SDAI
100  2014 Serum levels of visfatin, resistin and adiponectin in patients with psoriatic arthritis and associations with disease severity. PsA